RecruitingNot ApplicableNCT04078230

Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma


Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Enrollment

168 participants

Start Date

Jan 1, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

Intrahepatic cholangiocarcinoma (ICC) is one of the common malignant tumors. Lymph node metastasis is an important factor affecting the poor prognosis of intrahepatic cholangiocarcinoma. The eighth edition of the AJCC guidelines recommends at least 6 lymph nodes to be used for staging. The American Hepatobiliary and Pancreatic Association also recommends the removal of hilar lymph nodes as part of the radical surgery for intrahepatic cholangiocarcinoma. However, some scholars have found that patients with regional lymph nodes have similar survival rates. This contradictory result has prompted more scholars to conduct clinical research to explore the necessity and standardization of lymph node dissection in intrahepatic cholangiocarcinoma.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing two types of lymph node removal during surgery for intrahepatic cholangiocarcinoma — a type of liver cancer arising from bile duct cells inside the liver. Researchers want to find out whether removing more lymph nodes (extended lymphadenectomy) improves survival compared to removing only the nearby regional nodes. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with intrahepatic cholangiocarcinoma confirmed by imaging and pathology - Your cancer is considered surgically removable before the operation - Your imaging does not show obvious lymph node spread, or intraoperative biopsy of lymph nodes is negative - You have adequate liver function and enough healthy liver tissue remaining after surgery (more than 30%) **You may NOT be eligible if...** - You have significant heart, lung, brain, or kidney conditions making surgery too risky - Your cancer is not resectable or has already spread beyond the liver - You have inadequate liver function or insufficient remaining liver volume Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREExtend LymphAdenectomy

Expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and stations 12, 1, 3, 7, and 8 for left liver tumors


Locations(13)

The Johns Hopkins Hospital

Baltimore, Maryland, United States

China-Japan Friendship Hospital

Beijing, Beijing Municipality, China

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

Guangzhou, Guangdong, China

Hunan Provincial People's Hospital

Changsha, Hunan, China

The Affiliated Hospital of Inner Mongolia Medical University

Hohhot, Inner Mongolia, China

Renji Hospital Affiliated to Shanghai Jiao Tong University

Shanghai, Shanghai Municipality, China

Xinhua Hospital Affiliated to Shanghai Jiao Tong University

Shanghai, Shanghai Municipality, China

Zhong Shan Hospital Fudan University

Shanghai, Shanghai Municipality, China

The First Affiliated Hospital of Xi 'an Jiaotong University

Xi’an, Shanxi, China

West China Hospital Sichuan University

Chengdu, Sichuan, China

The Second Affiliated Hospital Zhejiang University School of Medicine

Hanzhou, Zhejiang, China

Zhejiang cancer hospital

Hanzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04078230


Related Trials